Literature DB >> 21686534

Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept.

Nimrod Maimon1, James Brunton, Adrienne Chan, Theodore K Marras.   

Abstract

In this case study, a 71 year old man with emphysema and severe rheumatoid arthritis, previously treated with a TNFα receptor antagonist, presented with progressive dyspnoea and weight loss. Thoracic imaging revealed extensive destruction of the left lung and this was associated with positive Mycobacterium xenopi cultures from respiratory samples. Anti-mycobacterial chemoptherapy was poorly tolerated and the patient subsequently died from respiratory failure and generalised wasting.

Entities:  

Year:  2009        PMID: 21686534      PMCID: PMC3027497          DOI: 10.1136/bcr.09.2008.0967

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  4 in total

1.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

Review 2.  Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases.

Authors:  Lisa G Criscione; E William St Clair
Journal:  Curr Opin Rheumatol       Date:  2002-05       Impact factor: 5.006

3.  Mycobacterium xenopi: innocent bystander or emerging pathogen?

Authors:  T M Jiva; H M Jacoby; L A Weymouth; D A Kaminski; A C Portmore
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

Review 4.  Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

Authors:  Michael A Gardam; Edward C Keystone; Richard Menzies; Steven Manners; Emil Skamene; Richard Long; Donald C Vinh
Journal:  Lancet Infect Dis       Date:  2003-03       Impact factor: 25.071

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.